Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon gamma-1b - Horizon Therapeutics plc

Next Previous
X
Search
Drug Profile

Interferon gamma-1b - Horizon Therapeutics plc

Alternative Names: Actimmune; IFNγ-1b; Imukin; Interferon-gamma-1b; Recombinant-gamma-interferon; Recombinant-interferon-gamma-1b

Latest Information Update: 06 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Fox Chase Cancer Center; Friedreichs Ataxia Research Alliance; Horizon Pharma; Horizon Therapeutics plc; InterMune
  • Class Antineoplastics; Antivirals; Interferons; Lymphokines
  • Mechanism of Action Immunomodulators; Interferon gamma stimulants; Nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic granulomatous disease; Pulmonary fibrosis; Friedreich's ataxia; Renal cell carcinoma; Osteopetrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic granulomatous disease; Osteopetrosis
  • Phase I/II Breast cancer
  • No development reported Hepatitis B; Hepatitis C; Solid tumours
  • Discontinued Atopic dermatitis; Cryptococcosis; Friedreich's ataxia; Hepatic fibrosis; Keloids; Mycoses; Non-Hodgkin's lymphoma; Ovarian cancer; Pulmonary fibrosis; Renal cell carcinoma; Systemic scleroderma; Tuberculosis

Most Recent Events

  • 20 Feb 2023 H. Lee Moffitt Cancer Center and Research Institute, in collaboration with Horizon Pharma Ireland completes a phase I/II trial in Breast cancer (Combination therapy) in USA (SC) (NCT03112590)
  • 14 May 2021 Pooled efficacy data from four trials in Idiopathic pulmonary fibrosis presented at the 117th International Conference of the American Thoracic Society (ATS-2021)
  • 27 Apr 2020 Interim safety and efficacy data from a phase II trial in Breast caner presented at the 111th Annual Meeting of the American Association for Cancer Research - I (AACR-2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top